Intravitreal Bevacizumab for Neovascular Glaucoma (IVB NVG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00384631
Recruitment Status : Completed
First Posted : October 6, 2006
Last Update Posted : February 15, 2008
Information provided by:
Shahid Beheshti University of Medical Sciences

October 4, 2006
October 6, 2006
February 15, 2008
April 2006
Not Provided
  • Change in intraocular pressure [ Time Frame: 6 months ]
  • Change in extent of iris neovascularization [ Time Frame: 6 months ]
Not Provided
Complete list of historical versions of study NCT00384631 on Archive Site
Best corrected visual acuity [ Time Frame: 6 months ]
Not Provided
Not Provided
Not Provided
Intravitreal Bevacizumab for Neovascular Glaucoma
Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial
Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.
Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
  • Neovascular
  • Glaucoma
  • Other: subconjunctival normal saline
    0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
  • Drug: Avastin
    intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
  • Sham Comparator: 2
    Intervention: Other: subconjunctival normal saline
  • Experimental: 1
    Intervention: Drug: Avastin
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
March 2007
Not Provided

Inclusion Criteria:

  • Clinical diagnosis of NVG
  • Vision less than 20/200
  • age 10-80 years

Exclusion Criteria:

  • Uncontrolled Blood Pressure
  • History of thromboembolism
  • Congestive Heart Failure
  • Renal Failure
  • Pregnancy or Lactation
  • Active ocular or periocular infection
  • No light perception
Sexes Eligible for Study: All
10 Years to 80 Years   (Child, Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
Not Provided
Not Provided
Not Provided
Shahid Beheshti University of Medical Sciences
Not Provided
Principal Investigator: Shahin Yazdani, MD Ophthalmic Research Center, Shaheed Beheshti Medical University
Shahid Beheshti University of Medical Sciences
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP